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It has been proposed that cell-mediated immunity 
and T-cell activation are key features in the 
pathogenesis of idiopathic nephrotic syndrome 
(NS). Numerous examples of abnormal immune 
responsiveness have been described in minimal 
change disease (MCD), and many of these 
observations have suggested a causal relationship 
between immune system and renal abnormalities1. 
In 1974, Shalhoub2 proposed that MCD was a 
disorder of lymphocyte function with increased 
levels of a lymphocyte-derived permeability factor. 
This hypothesis was based on several clinical 
observations that suggested the involvement of the 






DCs are rare, ubiquitously distributed, migratory 
antigen presenting cells (APCs), derived from 
CD34 bone marrow stem cells. In addition to 
having the unique capacity to prime naive T cells, 
DCs also regulate various effector cell functions 
and play central roles in modulating the immune 
response4. DCs are highly mobile cells and their 
sequential migration between tissues is 
accompanied by phenotypical and functional 
changes that are instrumental to their function as 
sentinels of the immune system5. They are being 
investigated in cancer biology, transplantation, and 
autoimmunity6. However, their role in initiating NS 
has not yet been studied. 
Original article 
Background: Dendritic cells (DCs) represent one of the most extensively 
studied topics in immunology, because of their central role in the induction 
and regulation of adaptive immunity, and because of their therapeutic 
potential for manipulating immune responses. 
Objectives: To evaluate circulating DC levels in pediatric patients with 
idiopathic nephrotic syndrome (NS) and its relation to disease activity in 
these patients. 
Methods: Fifteen nephrotic patients in relapse (proteinuria>40mg/m2/hour, 
hypoalbuminemia, and edema) before initiating steroid therapy (Group I), 
and another15 nephrotic patients in remission after withdrawal of steroid 
therapy (Group II) were compared to 15 age- and sex- matched healthy 
children. Besides clinical evaluation and routine laboratory investigations of 
nephrotic syndrome, circulating DCs were measured by flowcytometry.  
Results: Circulating DC count was lower in nephrotic patients in both 
proteinuria and remission groups [(48.89±13.52) and (64.64±7.69) 
X106/liter respectively] than in the control group (78.54±9.8) X106/liter with 
highly significant statistical difference (p<0.001), and lower in proteinuria 
group than the remission group with highly significant statistical difference 
(p<0.001). There was a positive correlation between DC count and serum 
albumin (moderate association) (p=0.002) and a negative correlation 
between DC count and urine protein /creatinine ratio (strong association) 
(p=0.001).  
Conclusion: Nephrotic syndrome was associated with decreased number of 
circulating DCs and the decrease was more apparent in patients with active 
disease. The positive correlation between DC counts and total protein, and 
serum albumin, and the negative correlation between DC count and urine 
protein/creatinine ratio point to the link between the decrease in DC count 
and the severity of the disease process. 
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Our study aimed to evaluate circulating DC 
levels in pediatric patients with idiopathic NS and 




This case-control, cross sectional study was 
conducted at the Pediatric Nephrology Clinic, 
Children's Hospital, and the Clinical Pathology 
Department of Ain Shams University in the period 
from October 2008 to June 2009. 
 
Study population: 
Patients: The study was conducted on 30 patients 
(19 males and 11 females) with NS followed up 
regularly in the clinic. They were classified into 2 
groups: 
Group I (proteinuria group): This group included 15 
nephrotic patients in relapse (proteinuria >40 
mg/m2/hour, hypoalbuminemia, and edema) before 
initiating steroid therapy. They were 7 males and 8 
females and their ages ranged from 2 .33 to 16 
years with a mean age of 6.11±3.75 years. 
Group II (remission group): This group included 15 
nephrotic patients in remission after withdrawal of 
steroid therapy. They were 12 males and 3 females; 
their ages ranged from 3.5 to 16 years with a mean 
age of 10.04 ± 3.85 years . 
Exclusion criteria: 
- Patients with any degree of renal impairment. 
- Patients with chronic inflammatory disorders as 
juvenile rheumatoid arthritis (JRA) and systemic 
lupus erythematosus (SLE). 
Control group: The control group comprised 15 
age- and sex-matched healthy children. They were 7 
males and 8 females, their ages ranged from 3 to 16 
years with a mean age of 8.47± 2.5 years . 
An informed verbal consent was obtained from the 
parents or caregivers of each child before 
enrollment in the study. 
Clinical evaluation 
History taking and clinical examination were 
carried out laying stress on symptoms and signs of 
NS, underlying etiology of NS, duration of the 
disease, response to steroid therapy, drug therapy 
other than steroids, measurement of blood pressure, 
body weight and height and assessment of body 
mass index (BMI). 
Laboratory investigations 
A- Routine investigations for NS including: 
- Urine protein/creatinine ratio on Synchrone Cx7 
system employing a time end point colorimetric 
method (GMI, Inc., USA). 
- Complete blood count by using automatic 
Coulter Counter (coulter micro Diff 18, Fullerton 
CA, USA). 
- Serum creatinine, total serum protein and serum 
albumin by using Hitachi automatic analyzer 917 
(Block Scientific, Inc., USA). 
B- Assay of circulating DC levels by flowcytometry 
(Beckman Coulter Epics XL Flow Cytometer, GMI, 
Inc., USA). 
Laboratory analysis: 
a- Sample collection and handling: 
Peripheral venous blood sample, about 1 cc, was 
collected from each subject under complete aseptic 
condition using EDTA as an anticoagulant and 
processed within 3 hours of collection. 
b- Procedure for dendritic cell measurement: 
Cells were Fc-blocked by treatment with 1 μg of 
human IgG/105 cells for 15 minutes at room 
temperature prior to staining. Then 25 μL of the Fc-
blocked cells were transferred to a 5 mL tube. Ten 
μL of fluorescein-conjugated anti-CD83 reagent 
were added and incubation was done for 30 - 45 
minutes at 2-8°C. Following this incubation, 
unreacted anti-CD83 reagent was removed by 
washing the cells twice in 4 mL of the same 
phosphate buffer saline (PBS). Finally, the cells 
were resuspended in 200 - 400 μL of PBS buffer for 
final flow cytometric analysis (Coulter Epics XL, 
USA). As a control for analysis, cells in a separate 
tube were treated with fluorescein-labeled mouse 
IgG1 antibody. Then results of the CD 83% and 
total leukocyte count were measured. Absolute 
counts of DCs were then obtained by multiplying 
the proportion of each DC subset within the total 
leukocyte population count. 
 
Statistical analysis 
The data were coded, entered and processed on 
computer using SPSS (version 15). Quantitative 
data were presented as mean ± SD (median and 
interquartile range for non parametric values). 
Comparison of the variables of the various groups 
was done using ANOVA test for normally 
distributed variables and least significant difference 
(LSD) post hoc test. Chi-square (χ2) test was used to 
compare the frequency of qualitative variables 
among the different groups. Correlation of various 
variables was done using Pearson r correlation test. 
Receiver operating characteristic curve (ROC 
curve) was drawn to detect diagnostic reliability of 
circulating DCs in nephrotic syndrome. For all tests 
a probability (p) less than 0.05 was considered 
significant and less than 0.001 was considered 
highly significant. 
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RESULTS 
Circulating DC count was lower in NS patients 
{both proteinuria (48.89±13.52) and remission 
(64.64±7.69) groups} than the control group 
(78.54±9.8) with highly significant statistical 
difference (p<0.001). Circulating DC count was 
lower in proteinuria group than remission group 
with highly significant statistical difference 
(p<0.001) (tables 1, 2).  
Plots of means and 95% confidence interval for 
DC count in the three groups revealed that there 
was no overlap between cases and controls.  This 
reflects the statistical significance and that a sharp 
cut off value can be defined. There was a minimal 
overlap between proteinuria group and remission 
group (figure 1). 
ROC (receiver operating characteristic curve) 
revealed that the area under the curve (AUC) for 
circulating DC count was 0.89 , i.e. circulating DC 
count is a very good differentiating parameter 
between relapse and remission at the cutoff value of 
58 with a sensitivity of 80% and a specificity of 
80% (figure 2) 
Correlation between circulating DC count and 
other clinical and laboratory parameters among 
patients revealed that there was positive significant 
correlation between circulating DC count and 
serum albumin (r = 0.54, p <0.05) (figure 3),  and a 
negative significant correlation between circulating 
DC count and urine protein/creatinine ratio (r = -
0.60, p<0.01) (figure 4). 
Comparison among the three groups with 
respect to clinical and routine laboratory findings 
revealed comparable mean systolic and diastolic 
blood pressure, Hb % and TLC (p>0.05). However, 
platelet count was higher in patients (both 
proteinuria 398.5±102.7×109/L and remission 
412.8±110.7×109/L groups) than the control group 
(230.6±33.9×109/L) with highly statistically 
significant difference (p<0.001), but there was no 
difference between both patients’ groups (p>0.05) 
(tables 3,4). 
There was no significant correlation between 
platelet count and DC count (r=0.1, p=0.58).
 
 
Table 1. DC count in the studied groups. 
Proteinuria group Remission group Control group 
Dendritic cells assay 
Mean ±SD Mean ±SD Mean ±SD 
F P Sig. 
DC count (×106/L) 48.89 ±13.52 64.64 ±7.69 78.54 ±9.80 29.30 <0.0001 HS 




Table 2. Multiple comparisons of the DC count using LSD test. 
   P Sig. 
Remission group <0.0001 HS 
Proteinuria group
Control group <0.0001 HS 
DC count  
(× 106/L) 
Remission group Control group <0.05 S 




Table 3. Comparison of some clinical and laboratory findings of the three groups. 
Proteinuria group Remission group Control group 
 
Mean ±SD Mean ±SD Mean ±SD 
F P Sig. 
Systolic blood pressure 101.33 ±8.34 102.00 ±14.24 97.00 ±11..92 0.80 0.46 NS 
Diastolic blood pressure 65.67 ±7.29 64.67 ±8.34 62.33 ±6.23 0.82 0.45 NS 
Platelets (×109/L) 398.5 ±102.7 412.8 ±110.7 230.6 ±33.9 19.27 <0.0001 HS 
Hb (g/dl) 11.54 ±1.23 11.67 ±0.83 11.03 ±1.15 1.43 0.25 NS 
TLC (×109/L) 8.01 ±1.48 7.76 ±0.89 7.33 ±1.70 0.91 0.41 NS 
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Table 4. Multiple comparisons for platelets using LSD test. 
   P Sig. 
Remission group 0.66 NS 
Proteinuria group
Control group <0.0001 HS 
Platelets  
(×109/L) 
Remission group Control group <0.0001 HS 
























































Proteinuria group Remission group Control group 
AUC =  0.89































r = 0.54, p = 0.002 r = - 0.60, p = 0.001 
Figure 3. Correlation between DC count  
and serum albumin 
Figure 4. Correlation between DC count  





To date, studies have yet not explored the 
circulating DCs levels in pediatric patients with NS. 
As such, our present analysis breaks new ground, 
providing novel insights into the involvement of 
DCs in the pathogenesis of NS. Much has been 
learned on the role of DCs from studies on other 
diseases such as SLE, lupus nephritis or chronic 
kidney disease (CKD). In consideration that DCs 
have entered the field of renal immunity because of 
their central role in the induction and regulation of 
adaptive immunity, and because of their therapeutic 
potential for manipulating immune responses; and 
the limited data on possible involvement of DCs in 
human renal diseases, we investigated whether 
patients with NS had alterations in circulating DCs. 
It has been proposed that cell mediated 
immunity and T-cell activation are key features in 
the pathogenesis of idiopathic NS1, as NS is 
associated with complex disturbances in the 
immune system, such as atopy and allergy, and a 
cytokine bias towards Th2 cytokines. Activation of 
T cells at the initial step of the immune response is 
dependent on the interaction with DCs through cell-
surface receptors7. We propose that T-cell 
disturbances in NS could be induced or promoted, 
at least in part, by alterations in DCs because these 
are key regulators of the immune system. We 
hypothesize that these events could help to initiate 
and maintain the autoimmune response in NS. 
In our study we found that the total number of 
circulating DCs was lower in patients with NS 
either those in proteinuria or those in remission than 
control group. Also we found that the total number 
of DCs was significantly affected by activity state 
of the patients with NS being significantly lower in 
patients with proteinuria than those in remission. 
This decrease in circulating DCs in NS correlates 
with specific clinical and serologic manifestations 
of the disease. There was a positive correlation 
between DC count and total serum protein, and 
serum albumin. There was also a negative 
correlation between DC count and urine 
protein/creatinine ratio. This may reflect the effect 
of proteinuria on level of DCs in peripheral blood 
which may be a part of the immune system 
affection in patient with NS. These correlations 
between DC count and other parameters found 
among patients but not found among control 
subjects, confirm the relation between NS and DCs . 
Considering the DCs biology, it might be 
possible to hypothesize two mechanisms by which 
DCs may mediate renal damage in NS. First, as 
DCs are an important source of several pro-
inflammatory factors4 ; it was suggested that DCs, 
activated via toll like receptors (TLR) or CD40L 
might locally release TNF-α and interleukins, 
enhancing renal inflammation8. Second, others’ 
findings in nephrotoxic glomerulonephritis that 
revealed proglomerular infiltration of renal DCs 
(rDCs) together with ours that showed a decrease in 
circulating DCs in NS, we suggest that DCs might 
migrate to local lymph nodes to present renal auto-
antigens to T and B lymphocytes directing an 
autoimmune response towards self tissue9. 
Our results are in accordance with those 
observed in other autoimmune diseases such as 
SLE, lupus nephritis, and AIDS; and in those 
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observed in allergic diseases such as asthma which 
may be associated with NS. Also our results are in 
accordance with those observed in other renal 
injury diseases e.g. CKD, nephrotoxic glomerulo-
nephritis and IgA nephropathy10,11,12. 
Fiore et al.10 analyzed circulating DCs in lupus 
nephritis patients which were compared to healthy 
controls. Lupus nephritis patients with active 
disease showed a significant reduction in total 
circulating DCs compared to patients in the 
remission state. Also lupus nephritis patients 
showed a significant reduction in total circulating 
DCs when compared to healthy controls. 
Some studies showed a decreased number of 
DCs in the peripheral blood of patients with 
SLE11,12. Gill et al.13 reported that both 
plasmacytoid DCs (pDCs) and myeloid DCs 
(mDCs) are decreased in SLE. 
In Hesselink et al.14 study on patients with 
CKD, they demonstrated that the total number of 
DCs was lowest among the group of adult patients 
on regular hemodialysis than those on conservative 
management and both are lower in comparison with 
a healthy control group. 
In IgA nephropathy, which is the most common 
biopsy-proven pattern of glomerulonephritis in the 
world15, it is most likely that the major cause of IgA 
deposition in the renal mesangium might be IgA 
itself16. In their study, Eijgenraam et al.17 showed 
that DCs of IgA nephropathy patients had a reduced 
capacity to induce IgA1 and IgA2 production in 
naїve B cells compared to DCs from control 
persons. 
Studies of asthma in humans as well as its 
animal models have also highlighted a critical role 
of DCs, as the most potent APC, that play a central 
role in initiating the primary immune response. On 
the basis of the distinct properties of the DC 
subtypes, mDCs and pDCs were considered to be 
specialized APC inducing a Th1 and Th2 response, 
respectively. In asthma, it is suggested that 
increased pDCs relative to mDCs may be involved 
in the Th2-biased immune responses18. 
Reduced DC numbers were reported in HIV 
primary infection and were partially restored by 
antiretroviral therapy19. DC-based vaccines for 
chronic HIV-1 infection have been shown to be safe 
and feasible20,21. 
Moreover, our results revealed that there was a 
significant increase in platelets in NS patients either 
those in activity state or those who were in 
remission when compared to control group. This 
supports the hypothesis that platelets may play a 
significant role in generating coagulability in NS22.  
In agreement with our finding, Shattil et al.23 who 
detected increased platelets, using flow cytometric 
analysis in NS patients. 
In conclusion, DC counts were markedly 
reduced in the blood of patients with NS compared 
with healthy volunteers. Moreover, DC counts were 
markedly reduced in patients with proteinuria in 
comparison with the remission group. We 
hypothesized that this decrease could help to initiate 
and maintain the autoimmune process in NS. The 
positive correlation between DC counts and total 
protein, and serum albumin, and the negative 
correlation between DC count and urine 
protein/creatinine ratio point to the link between the 
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